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with health-related quality of life?
Lizheng Shi1*, Hui Shao1, Yingnan Zhao2 and Nina A Thomas3Abstract
Objective: Patients may fear the symptoms and consequences associated with hypoglycemia. We tested whether
fear of hypoglycemia is independently associated with poorer health-related quality of life (HRQOL).
Research design and methods: Data were collected using direct-mail survey and enrollment information from
adult commercial health plan enrollees with type 2 diabetes during a 12-month period (12/01/2008 to 11/30/2009).
HRQOL was evaluated by the EuroQol (EQ)–5D index and 12-item Short Form Health Survey Mental Component
Summary (SF-12 MCS) and Physical Component Summary (SF-12 PCS). Fear of hypoglycemia was assessed using the
Hypoglycemia Fear Survey (HFS). Two ordinary least-squares (OLS) models of HRQOL controlling for demographics and
illness characteristics were specified, and OLS regression coefficients and statistical inferences were compared. Model 1
included 1 variable of hypoglycemia symptoms; Model 2 included both hypoglycemia symptoms and HFS score.
Results: Of 3999 patients contacted, 813 responded to the survey. Model 1: hypoglycemia symptoms alone were
associated with worse HRQOL (SF-12 MCS and SF-12 PCS scores and EQ-5D utility score; all P < 0.05). Model 2:
hypoglycemia symptoms were significantly associated only with SF-12 MCS score. HFS total score was significantly
associated with all 3 HRQOL scores. Hypoglycemia symptoms, Hispanic ethnicity, and longer diabetes duration were
associated with greater hypoglycemia fear. Higher income, white race, and treatment without sulfonylurea or insulin
were associated with less hypoglycemia fear (all P < 0.05).
Conclusions: In addition to the effect of symptomatic hypoglycemia on HRQOL, fear of hypoglycemia was
independently associated with lower overall health status and mental and physical health.
Keywords: Antidiabetic agents, Health status, Hypoglycemia, Outcome assessment, Quality of life, Type 2 diabetesHypoglycemia is associated with increased risk of a variety
of adverse clinical outcomes in patients with type 2 dia-
betes, including microvascular events (eg, nephropathy, ret-
inopathy, neuropathy), macrovascular events (eg, heart
failure, peripheral vascular disease, myocardial events,
stroke), and death [1-3]. High rates of hypoglycemia symp-
toms (38%–63%) [4-6] and hypoglycemia episodes (14%–
23%; based on low blood sugar) [7,8] are observed in
patients with type 2 diabetes in general clinical practice.
Hypoglycemia is primarily associated with treatment
with insulin and insulin secretagogues [9]. A nation-
wide cohort study demonstrated that patients who ex-
perience hypoglycemia are more likely to be using
insulin and sulfonylureas than those who do not* Correspondence: lshi1@tulane.edu
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unless otherwise stated.experience hypoglycemia. Hypoglycemia, use of insulin,
and use of sulfonylureas are associated with increased
risk for major cardiovascular (CV) events, CV disease,
and death [3]. Risk of hypoglycemia also increases with
age and duration of diabetes [10].
Patients may fear the symptoms associated with a mild
episode of hypoglycemia as well as the consequences of
severe hypoglycemia, which may include seizure or loss
of consciousness [11].
Fear of hypoglycemia is a considerable problem in pa-
tients with diabetes [5,12] and may itself represent a barrier
to glycemic control. Hypoglycemia is associated with lower
health-related quality of life (HRQOL) [5,7,8,13], depression
[7], and lower treatment satisfaction [4,5], which could
undermine treatment adherence [7]. Fear of hypoglycemia
may lead to preventive coping behaviors, such as taking less
insulin or increasing food intake [12,14], that negatively. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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physicians to limit the aggressiveness of therapy [15].
In a cross-sectional survey study, we found that
symptomatic hypoglycemia was associated with worse
HRQOL as well as greater fear of hypoglycemia [16].
Compared with patients who did not report a history of
symptomatic hypoglycemia, patients with a confirmed
history of symptomatic hypoglycemia had higher scores
on the Hypoglycemia Fear Survey (HFS) Behavior and
Worry subscales (indicating more fear of and worry
about hypoglycemia; each P < 0.001), lower scores on
the EuroQol (EQ)–5D index (indicating poorer health
status, P < 0.001), and lower scores on the 12-item
Short Form Health Survey (SF-12) Mental Component
Summary (MCS) score (P < 0.001) and Physical Compo-
nent Summary (PCS) score (P = 0.002). The objective of
this retrospective analysis was to examine the relationships
among symptomatic hypoglycemia, patient self-reported
fear of hypoglycemia, and HRQOL while controlling for
patient baseline demographic and disease characteristics.
We tested the hypothesis that, beyond the effect of
symptomatic hypoglycemia itself on patient HRQOL, fear
of hypoglycemia is independently associated with lower
HRQOL.Research design and methods
Study design
Detailed methodology for this cross-sectional observa-
tional research study was previously published [16]. The
study combined patient-reported data collected through
mail surveys and retrospective analysis of administrative
claims data (medical data, pharmacy data, and enroll-
ment information) from a large US health plan (the Life
Sciences Research Database). The study protocol was ap-
proved by a central institutional review board (IRB) prior
to study initiation. And due to the fact that the patients
in our study were identified from administrative claims
data, the study concept was also approved by the large
US health plan prior to commencement of the study.
Participants were adult enrollees in the health plan with
a diagnosis of type 2 diabetes and ≥2 pharmacy claims
for an oral antidiabetic medication (OAD) with or with-
out insulin identified in the administrative claims data
from December 1, 2008, to November 30, 2009.Patient survey
For the survey, patients (N = 3999) were contacted dir-
ectly by mail. The patient survey assessed demographic
variables, age at time of type 2 diabetes diagnosis, family
history of diabetes, and smoking status. Patients were
asked about their current OAD, duration of treatment,
and modifications to their treatment within the previous
6 months. Medication adherence was assessed using theMorisky self-report medication adherence 4-item ques-
tionnaire [17].
Fear of hypoglycemia was evaluated using the HFS
[18]. This validated assessment lists 15 behaviors that
patients may engage in to avoid low blood sugar, with
potential consequences, and 18 items related to low
blood sugar about which patients with diabetes may be
concerned. The recall period was 6 months. A total
score, Behavior subscale score (sum of the 15 behavioral
items), and Worry subscale score (sum of the 18 worry
items) were generated. In addition, patients were asked
whether they had changed their medication or were
afraid to change medications because of hypoglycemia.
Health-related quality of life was assessed using 2 in-
struments. Overall health status was assessed using the
EQ-5D, a standardized measure that rates 5 dimensions
of health (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression) across 3 levels (no prob-
lems, some/moderate problems, and extreme problems)
[19,20]. The index value (ie, health utility) between 0
(death) and 1 (perfect health) was calculated using the
value sets (weights) from a US population sample. The
other instrument was the SF-12 [21], which can produce
an MCS and a PCS. Summary scores range from 0 to
100, with a higher score indicating a better quality of life
in mental and physical components. Hypoglycemia was
defined based on American Diabetes Association symp-
toms [22] and blood glucose readings at the time that
symptoms occurred.
The survey packet we used in this study contained a
pre-paid cash incentive of $10 to the patients, along with
the invitation letter printed on letterhead, the IRB-
approved consent form, the survey instrument printed
in booklet form, and a postage-paid business reply enve-
lope. We sent reminders to the patients 2 and 4 weeks
following the initial survey to increase our response rate.
Statistical analyses
Survey variables (eg, demographics and clinical characteris-
tics) were analyzed descriptively, and bivariate comparisons
of demographic characteristics and outcome measures were
performed using appropriate tests (eg, t-test or chi-square
test) based on the distribution of the measure. Multivariate
analyses of HFS, SF-12, and EQ-5D outcomes were con-
ducted using ordinary least squares. Specific predictors
(ie, explanatory variables) to be included were selected pri-
marily based on clinical rationale. Associations among
symptomatic hypoglycemia, fear of hypoglycemia, and
HRQOL were modeled in 2 ordinary least-squares regres-
sions, controlling for sociodemographics, illness character-
istics, and treatment factors [16]. Model 1 of the HRQOL= f
(symptomatic hypoglycemia) tested the associations be-
tween symptomatic hypoglycemia and HRQOL, and based
on previously published results [16], these were expected to
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assessment of the study hypothesis, added 1 additional vari-
able of hypoglycemia fear and tested the impact that fear of
hypoglycemia had on health status independently of the
impact of hypoglycemia symptoms. Following standard
procedure, regression diagnostics were performed to assess
goodness of fit and violations of model assumptions (eg,
multicollinearity, heteroskedasticity) for each model. Any
violations of the model were noted and appropriate correc-
tions made to the data. The fitted and observed data were
examined to uncover outliers, their effect on the analysis,
and possible misspecification of the initial equation. SAS
9.2 software (SAS Institute, Inc., Cary, NC) was used for
statistical analyses [23]. The significance level was set at
0.05 (2-tailed).
Because different classes of antidiabetic drugs may be
more likely to cause hypoglycemia [24-27], the association
between fear for hypoglycemia and quality of life might
also be different across different patient subgroups of anti-
diabetic medication users. Due to this concern, the same
statistical analysis procedures were conducted on two pa-
tient subgroups of antidiabetic medication users: insulin
users and sulfonylurea users.
Results
Patient survey results
Of 3999 patients contacted, 813 responded with a
complete survey (response rate, 20.3%). Of these, 578
(71.1%) reported ≥1 hypoglycemia symptom within the
previous 3 months. Among the population characteristics
assessed, only OAD group and sex showed a statistically
significant difference between patients with and without
symptomatic hypoglycemia (Table 1). Patients in the OAD
plus insulin group were more likely to report ≥1
hypoglycemia symptom (83.3% [244/293]) compared with
those in the sulfonylurea without insulin group (69.9%
[172/246]) or the nonsulfonylurea OAD without insulin
group (59.1% [162/274]; P < 0.001). Significantly more
women (77.1% [263/341]) than men (66.7% [315/472]) re-
ported ≥1 hypoglycemia symptom.
Symptomatic hypoglycemia was associated with more
fear of hypoglycemia (higher total HFS score) and worse
HRQOL (lower SF-12 MCS, SF-12 PCS, and EQ-5D
scores; each, P < 0.05; Figure 1). Table 2 presents the asso-
ciations between the HFS and various factors. The pres-
ence of symptomatic hypoglycemia was associated with
greater fear of hypoglycemia and had the strongest associ-
ation (regression coefficient >10 points of HFS total score,
P < 0.0001). Other factors also showed statistically signifi-
cant associations (Table 2). Higher income was associated
with less fear of hypoglycemia (P < 0.0001), as was white
racial categorization compared with nonwhite racial
categorizations (P < 0.0001). Hispanic ethnicity was associ-
ated with greater fear of hypoglycemia (P = 0.03). Longerduration with a diagnosis of diabetes and better self-
reported adherence were also associated with greater fear
of hypoglycemia (each P < 0.0001).
The ordinary least-squares model of HRQOL using
symptomatic hypoglycemia only and controlling for
demographics and illness characteristics (Model 1,
Table 3) yielded regression coefficients for symptomatic
hypoglycemia on HRQOL scores. The associations be-
tween symptomatic hypoglycemia and EQ-5D score
and SF-12 MCS score were statistically significant (each
P < 0.05). In Model 2, which included the additional
variable of HFS, the HFS score was significantly associ-
ated with scores on all 3 HRQOL outcomes (each P <
0.0001), whereas symptomatic hypoglycemia showed a
statistically significant association only for the SF-12
MCS (P = 0.022). The fully specified regression models
for Table 3 are provided in Additional file 1: Tables
S1.1-S1.6.
Subgroup analyses were conducted for insulin users
(Table 4) and sulfonylurea users (Table 5). For insulin
users (n = 293), Model 1 showed that the symptomatic
hypoglycemia was not associated with 3 HRQOL scores
(each P > 0.05). Model 2 showed that the HFS score
was still significantly associated with scores on all 3
HRQOL outcomes (each P < 0.05), whereas symptomatic
hypoglycemia showed no statistically significant associ-
ation with any of the 3 HRQOL outcomes (each P > 0.05).
For sulfonylurea users (n = 246), Model 1 showed that the
symptomatic hypoglycemia was associated with EQ-5D
scores and SF-12 MCS scores (each P < 0.05). Model 2
showed that the HFS score was significantly associated with
scores on all 3 HRQOL outcomes (each P < 0.05), whereas
symptomatic hypoglycemia was only significantly associated
with EQ-5D scores and SF-12 MCS scores (each P < 0.05).
The fully specified regression models for Table 4 and
Table 5 are provided in Additional file 1: Tables S2.0-S3.5.
Discussion
In patients with type 2 diabetes treated with antihyper-
glycemic therapy, hypoglycemia imposes a significant
physical and psychological burden [28]. Previously, we
demonstrated that hypoglycemia is significantly associ-
ated with poorer HRQOL as well as increased fear of
hypoglycemia [16]. Other studies have shown an associ-
ation between the severity of hypoglycemia and in-
creased fear of hypoglycemia [29-31]. This retrospective
analysis was conducted to test the hypothesis that fear of
hypoglycemia is itself independently associated with
poorer HRQOL. Results support this hypothesis, demon-
strating a significant independent association between
fear of hypoglycemia and scores on the EQ-5D and SF-
12 PCS and MCS. This relationship was demonstrated
for both insulin and sulfonylurea users. These results are
consistent with previous cross sectional studies that have
Table 1 Population characteristics between patients who reported versus those who did not report symptoms of
hypoglycemia
Characteristic, n (%) No hypoglycemia (n = 235) Hypoglycemia (n = 578) P value*
Age, y
<65 203 (86.4) 525 (90.8) 0.0603
≥65 32 (13.6) 53 (9.2)
Sex
Female 78 (33.2) 263 (45.5) 0.0013
Male 157 (66.8) 315 (54.5)
Family history of diabetes
No 58 (26.9) 110 (20.4) 0.0528
Yes 158 (73.2) 430 (79.6)
Treatment
Any OAD with insulin 49 (20.9) 244 (42.2)
SU without insulin 74 (31.5) 172 (29.8) <.0001
Non-SU OAD without insulin 112 (47.7) 162 (28.0)
Diabetes treatment period, y
<1 45 (19.2) 96 (16.7) 0.4765
1–2 70 (29.9) 151 (26.3)
3–5 63 (26.9) 167 (29.1)
6–10 36 (15.4) 91 (15.9)
>10 20 (8.6) 69 (12.0)
Ethnicity
White
No 52 (22.5) 161 (28.3) 0.0961
Yes 179 (77.5) 409 (71.8)
Black or African American
No 196 (84.9) 469 (82.3) 0.3806
Yes 35 (15.2) 101 (17.7)
Hispanic or Latino
No 209 (89.7) 525 (92.3) 0.2360
Yes 24 (10.3) 44 (7.7)
Marital status
Single, never married 25 (10.7) 68 (11.8) 0.6079
Married 167 (71.4) 390 (67.7)
Divorced 32 (13.7) 82 (14.2)
Separated 2 (0.9) 14 (2.4)
Widowed 8 (3.4) 22 (3.8)
Annual household income, $US
<25,000 13 (5.9) 44 (8.0) 0.7025
25,000–49,999 68 (30.6) 169 (30.8)
50,000–74,999 42 (18.9) 116 (21.1)
75,000–99,999 36 (16.2) 78 (14.2)
>100,000 63 (28.4) 142 (25.9)
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Table 1 Population characteristics between patients who reported versus those who did not report symptoms of
hypoglycemia (Continued)
Education
Less than secondary 9 (3.9) 14 (2.5) 0.8425
Some secondary 4 (1.7) 14 (2.5)
Secondary or equivalent 53 (22.8) 131 (22.9)
Tertiary but no degree 60 (25.8) 166 (29.0)
2-year undergraduate degree 28 (12.0) 59 (10.3)
>2-year undergraduate degree 51 (21.9) 199 (20.8)
Graduate school 28 (12.0) 69 (12.1)
US Region
Northeast 13 (5.5) 33 (5.7) 0.2144
Midwest 29 (12.3) 54 (9.3)
South 181 (77.0) 440 (76.1)
West 12 (5.1) 51 (8.8)
Morisky adherence
Low 123 (52.8) 265 (46.3) 0.3058
Relatively low 71 (30.5) 186 (32.5)
Middle 28 (12.0) 77 (13.4)
Relatively high 10 (4.3) 36 (6.3)
High 1 (0.4) 9 (1.6)






































Figure 1 Comparison of health-related quality-of-life scores and fear of hypoglycemia between patients who reported (n = 235) vs
those who did not report (n = 578) symptoms of hypoglycemia. EQ-5D=EuroQol-5D scale; HFS = Hypoglycemia Fear Survey; MCS = Mental
Component Summary; PCS = Physical Component Summary; SF-12 = 12-item Short Form Health Survey. *P < 0.0001, †P = 0.0007 by t test.
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P value 95% CI
Lower Upper
Hypoglycemia 10.47 1.28 <0.0001 7.95 12.99
Age (<65 y)
≥65 y −1.23 1.91 0.52 −4.98 2.51
Sex (male)
Female −1.76 1.23 0.15 −4.17 0.66
Body mass index −0.10 0.08 0.22 −0.25 0.06
Family history of diabetes −0.58 1.37 0.67 −3.27 2.10
Treatment (SU without insulin)
Non-SU OAD without insulin −2.25 1.44 0.12 −5.09 0.58
Any OAD with insulin 2.09 1.42 0.14 −0.71 4.89
Duration of current diabetes medication −0.70 0.47 0.14 −1.63 0.23
Ethnicity
White (not white) −4.56 1.35 <0.0001 −7.22 −1.91
Hispanic or Latino (not Hispanic or Latino) 4.74 2.13 0.03 0.56 8.92
Married (currently not married) −0.04 1.29 0.97 −2.59 2.50
Household income level −1.94 0.47 <0.0001 −2.86 −1.03
Education (less than secondary) 0.75 3.56 0.83 −6.25 7.75
Region (Northeast)
Midwest 1.24 2.82 0.66 −4.29 6.77
South 1.41 2.33 0.55 −3.17 5.99
West 0.21 3.14 0.95 −5.96 6.37
Diabetes duration (y) 0.36 0.08 <0.0001 0.20 0.52
Morisky adherence 1.72 0.60 <0.0001 0.54 2.91
OAD = oral antidiabetic medication; SU = sulfonylurea.
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HRQOL [29,32].
A significant association was observed between symp-
tomatic hypoglycemia and EQ-5D and SF-12 MCS
scores in Model 1, whereas only the association with SF-
12 MCS was significant after incorporating the HFS into
the model. In contrast, fear of hypoglycemia demon-
strated a significant association with all 3 HRQOL out-
comes. This finding suggests that, statistically, fear of
hypoglycemia may be a more important predictor thanTable 3 Role of hypoglycemia fear on health-related quality o
Variable EQ-5D (US) SF-12 MCS
β P value 95% CI for β β P va
Model 1
Hypo 0.041 0.002 −0.067 to −0.015 −3.628 <0.0
Model 2
Hypo −0.014 0.303 −0.040 to 0.013 −1.937 0.02
HFS −0.003 <0.0001 −0.003 to −0.002 −0.162 <0.0
β = regression coefficient; EQ = EuroQol; Hypo = symptomatic hypoglycemia; HFS = H
Component Summary; SF-12 = 12-item Short Form Health Survey.hypoglycemia itself of patient well-being and health
status.
Multiple factors associated with fear of hypoglycemia
were identified. Consistent with our study [16] and other
reports [29,31,33], symptomatic hypoglycemia had the
strongest (positive) association with fear of hypoglycemia.
Thus, it appears that in patients with type 2 diabetes, ex-
periencing an event of hypoglycemia increases rather than
diminishes fear of such an event. An important clinical
practice implication of this finding is the need forf life using alternative models
SF-12 PCS
lue 95% CI for β β P value 95% CI for β
001 −5.259 to −1.998 −0.974 0.247 −2.623 to 0.675
2 −3.591 to −0.283 0.579 0.500 −1.104 to 2.262
001 −0.210 to −0.115 −0.149 <0.0001 −0.197 to −0.101
ypoglycemia Fear Survey; MCS =Mental Component Summary; PCS = Physical
Table 4 Role of hypoglycemia fear on health-related quality of life using alternative models (Insulin Subgroup)
Variable EQ-5D (US) SF-12 MCS SF-12 PCS
β P value 95% CI for β β P value 95% CI for β β P value 95% CI for β
Model 1
Hypo −0.001 0.96 −0.058 to 0.055 −2.506 0.137 −5.813 to 0.801 −1.668 0.359 −5.244 to 1.908
Model 2
Hypo 0.029 0.311 −0.027 to 0.086 −0.285 0.863 −3.534 to 2.965 −0.358 0.847 −4.011 to 3.296
HFS −0.003 <0.001 −0.004 to −0.001 −0.188 <0.0001 −0.259 to −0.116 −0.111 <0.007 −0.191 to −0.031
β = regression coefficient; EQ = EuroQol; Hypo = symptomatic hypoglycemia; HFS = Hypoglycemia Fear Survey; MCS =Mental Component Summary; PCS = Physical
Component Summary; SF-12 = 12-item Short Form Health Survey.
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hypoglycemia and take steps to address this fear and re-
lated behaviors.
In the current analysis, Hispanic/Latino ethnicity, dur-
ation of diabetes, and self-reported adherence also
showed a positive association with fear of hypoglycemia,
whereas household income and white race showed a
negative association. These data suggest that demo-
graphic variables might be helpful in predicting those
patients most likely to experience fear of hypoglycemia.
The positive association between duration of diabetes
and fear of hypoglycemia could reflect greater insulin
use in patients with a longer duration of disease. Alter-
natively, an independent association between these vari-
ables would seem to further indicate that experiencing
hypoglycemia increases fear of the event.
As no causality can be inferred in this cross-sectional
analysis, the positive relationship between self-reported
adherence and fear of hypoglycemia is difficult to inter-
pret. In a previous study, patients reporting hypoglycemia
symptoms were more likely to report barriers to adher-
ence (eg, bothered by medication side effects, unable to
follow plans) [4]. In addition, data suggest that patients
who have experienced a hypoglycemic episode are likely
to initiate preventive behaviors that may include modifica-
tion of their dosing regimen [14,16]. Although these find-
ings may seem at odds with one another, it is reasonable
to expect that patients adherent to strict glycemic control
regimens would have more reason to be fearful of
hypoglycemia. Additional studies with longitudinal dataTable 5 Role of hypoglycemia fear on health-related quality o
Variable EQ-5D (US) SF-12 MCS
β P value 95% CI for β β P va
Model 1
Hypo −0.077 0.001 −0.123 to −0.031 −6.531 <0.0
Model 2
Hypo −0.060 0.014 −0.107 to -0.013 −5.300 0.00
HFS −0.002 0.014 −0.004 to −0.000 −0.140 0.00
β = regression coefficient; EQ = EuroQol; Hypo = symptomatic hypoglycemia; HFS = H
Component Summary; SF-12 = 12-item Short Form Health Survey.collection are needed to fully understand the variables that
predict fear of hypoglycemia.
Predictors of hypoglycemia in patients with type 2 dia-
betes are better understood. In the current analysis, more
women versus men and more patients treated with OAD
plus insulin versus sulfonylurea without insulin or nonsul-
fonylurea OAD without insulin reported hypoglycemia.
The difference in hypoglycemia with respect to diabetes
therapy is to be expected, given that insulin and insulin se-
cretagogues are the most common cause of hypoglycemia
in patients with type 2 diabetes [15]. The observation that
more women than men reported hypoglycemic symptoms
was unexpected but has been observed in another study
[29] and could possibly reflect sex-related differences in
self-reporting of hypoglycemic symptoms.
This analysis has some limitations. Because the study
was cross-sectional, no causal relationships can be in-
ferred from the findings. Data on the frequency and se-
verity of hypoglycemic episodes were not collected so
their contribution to fear of hypoglycemia could not be
assessed. Also, because the survey design used a con-
venience sample of patients that included only those
who were members of specific health plans, with volun-
tary participation, survey participants may not be repre-
sentative of all patients with type 2 diabetes. The study
also relied on patient self-report, and the survey had a
patient recall period of 6 months. Longitudinal cohort
studies are warranted to further understand the impact
of hypoglycemia and to test potential interventions to
address the issue of hypoglycemia fear to improve healthf life using alternative models (Sulfonylurea Subgroup)
SF-12 PCS
lue 95% CI for β β P value 95% CI for β
01 −9.606 to −3.456 −1.815 0.241 −4.857 to 1.226
1 −8.453 to −2.147 0.056 0.971 −2.973 to 3.084
8 −0.243 to −0.038 −0.213 <0.001 −0.311 to −0.114
ypoglycemia Fear Survey; MCS =Mental Component Summary; PCS = Physical
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symptomatic hypoglycemia itself, fear of hypoglycemia
was independently associated with lower HRQOL (over-
all health status, mental health, and physical health) in
patients with type 2 diabetes. There is an unmet need
for patient education programs that address patient fear
of hypoglycemia and use of medications with a lower
risk of hypoglycemia.Additional file
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